Fairvalue-Calculator Fairvalue-Calculator
EN DE

NextCell Pharma AB (NXTCL) Fair Value & Analysis

Healthcare · SE · Market cap 124M SEK

Pricekr 1.03
Fair Valuekr 0.4000
Upside-61.1%
Quality95/100
Evidence: Low Range kr 0.2600 – kr 0.4900

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

NextCell Pharma AB (NXTCL) currently trades at kr 1.03, while our model-based Fair Value estimate is kr 0.4000 — implying the stock looks roughly 61.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is NextCell Pharma AB (NXTCL) undervalued?
As of Jun 25, 2026, our model estimates a fair value of kr 0.4000 versus a price of kr 1.03 — about −61% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NXTCL?
Our 21-model fair value for NextCell Pharma AB is kr 0.4000 (as of Jun 25, 2026), built from audited fundamentals. The current price is kr 1.03.
What is the quality score of NXTCL?
NextCell Pharma AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.